Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22456033 | 0.85 | KAT2B (0.61) | HCAR3HTTMAPTALDH1A1CDC25B | |
| SCHEMBL6536602 | 0.84 | HCAR3 (0.62) | HCAR3HTTMAPTALDH1A1KAT2B | |
| SCHEMBL9458121 | 0.83 | HCAR3 (0.54) | HCAR3HTTMAPTALDH1A1CDC25B | |
| SCHEMBL11539572 | 0.83 | MAPT (0.61) | HTTMAPTALDH1A1TDP1MAPK1 | |
| SCHEMBL19858249 | 0.83 | HCAR3 (0.61) | HCAR3MAPTALDH1A1MAPK1 | |
| SCHEMBL5103407 | 0.81 | HCAR3 (0.64) | HCAR3MAPTALDH1A1KAT2BTDP1 | |
| SCHEMBL1886423 | 0.81 | ALDH1A1 (0.62) | HCAR3MAPTALDH1A1KAT2BTDP1 | |
| SCHEMBL22115089 | 0.80 | HCAR3 (0.55) | HCAR3HTTMAPTALDH1A1CDC25B | |
| SCHEMBL18074957 | 0.80 | HCAR3 (0.54) | HCAR3MAPTALDH1A1KAT2BKMT2A | |
| SCHEMBL18074958 | 0.80 | HCAR3 (0.54) | HCAR3MAPTALDH1A1KAT2BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053212-B2 | Benzimidazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| CN-107635989-B | Benzimidazole derivatives as bromodomain inhibitors | 葛兰素史克知识产权开发有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20200039953-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| US-10442786-B2 | Benzimidazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| EP-3549939-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-09 | — | — | EP | disclosed |
| EP-3271349-B1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-05-15 | — | — | EP | disclosed |
| US-20180044317-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| EP-3271349-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016146738-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-22 | — | — | WO | disclosed |
| US-5258370-A | Artificial redox enzymes | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1993-11-02 | — | — | US | disclosed |
| WO-1992017508-A1 | ARTIFICIAL REDOX ENZYMES | UNIVERSITY OF MISSOURI (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442786-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD1, BRPF3 | HCAR3 982/4885HTT 3791/4885MAPT 3681/4885 |
| US-20200039953-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD1, BRPF3 | HCAR3 982/4885HTT 3791/4885MAPT 3681/4885 |
| US-20180044317-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD1, BRPF3 | HCAR3 982/4885HTT 3791/4885MAPT 3681/4885 |
| US-11053212-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD1, BRPF3 | HCAR3 982/4885HTT 3791/4885MAPT 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.